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Novel Negative Allosteric Modulator Inhibits Small Conductance Ca2+-Activated K+-
Channels and Selectively Prolongs Atrial Refractoriness in Conscious Pigs 
 
 
Rafel Simó Vicens1,2, Carlotta Citerni1,2, Nils G. Edvardsson3, Ulrik S. Sørensen2, Morten Grunnet2, 
Jonas G. Diness2, Bo H. Bentzen1,2 
1Biomedical Institute, University of Copenhagen, Copenhagen, Denmark 
2Acesion Pharma, Copenhagen, Denmark. 
3Sahlgrenska University Hospital, Gothenburg, Sweden 
 
Background: Small conductance Ca2+-activated K+-channels (SK channels) represent a promising 
atrial-selective target for treatment of atrial fibrillation (AF). Establishing the molecular mechanism 
for SK channel inhibition by small molecules is important for generating new drugs. 
 
Objective: To establish the mechanism of SK inhibition by AP14145 and to confirm a prolongation 
of the atrial effective refractory period (AERP) in pigs without comparable effects in the ventricles. 
 
Methods: Using site directed mutagenesis the putative drug binding site of AP14145 was 
established AP14145 subtype selectivity and mechanism of action were investigated by inside-out 
and whole cell patch clamp recordings of expressed SK channels. A selectivity profile of AP14145 
was performed on heterologous expressed channels. Effects of AP14145 (i.v. infusion of 5 mg/kg 
over 30 min) on the AERP were recorded in three conscious healthy pigs using an implanted 
pacemaker. 
Results: AP14145 was found to be a selective negative allosteric modulator of SK2 and SK3 
channels. The presence of AP14145 10 µM increased the EC50 of Ca
2+ from 0.37 ± 0.02 µM (n=9) 
to 1.2 ± 0.1 µM (n=7). This inhibitory effect depended on two amino acids, S508 and A533 found in 
the inner pore helix of S5 and S6, as earlier found for another negative SK channel modulator 
NS8593 indicating a common binding site AP14145 did not display subtype selectivity (IC50 = 1.1 ± 
0.3 µM SK2 vs IC50 = 1.1 ± 0.3µ M SK3, n=7). In the three conscious pigs, AP14145 increased the 
AERP by 40 ms (22%), 32 ms (22%) and 20 ms (18%) without prolonging the QTcB, -7 ms (-2%), -
16ms (-4%) and +38 ms (+8%) , respectively. 
 
Conclusions: AP14145 is a selective negative allosteric modulator of SK2 and SK3 that shifts the 
calcium dependence of channel activation, an effect dependent on two identified amino acids. 
Moreover, SK current inhibition prolongs atrial refractoriness in conscious healthy pigs without 
affecting the QT interval, thereby highlighting SK channels as an atrial-selective target. The 
understanding of how SK inhibition is accomplished at the molecular level should help future 
development when targeting SK channels for the treatment of AF. 
